PURPOSE: VM202, a newly constructed plasmid human hepatocyte growth factor, was transferred intramyocardially after infarction for the purpose of evaluating this strategy as a therapeutic approach for protection from left ventricular (LV) remodeling. MATERIALS AND METHODS: The institutional animal care and use committee approved this study. Pigs underwent coronary artery occlusion and reperfusion and served as either control (n = 8) or VM202-treated (n = 8) animals. VM202 was transferred intramyocardially into four infarcted and four periinfarcted sites. Cardiac magnetic resonance (MR) imaging (cine, perfusion, delayed enhancement) was performed in acute (3 days) and chronic (50 days +/- 3 [standard error of the mean]) infarction. Histopathologic findings were used to characterize and quantify neovascularization. The t test was utilized to compare treated and control groups and to assess changes over time. RESULTS: In acute infarction, MR imaging estimates of function, perfusion, and viability showed no difference between the groups. In chronic infarction, however, VM202 increased maximum signal intensity and upslope at first-pass perfusion imaging and reduced infarct size at perfusion and delayed-enhancement imaging. These changes were associated with a decrease in end-diastolic (2.15 mL/kg +/- 0.12 to 1.73 mL/kg +/- 0.10, P < .01) and end-systolic (1.33 mL/kg +/- 0.07 to 0.92 mL/kg +/- 0.08, P < .001) volumes and an increase in ejection fraction (38.2% +/- 1.3 to 47.0% +/- 1.8, P < .001). In contrast, LV function deteriorated further in control animals. Compared with control animals, VM202-treated animals revealed peninsulas and/or islands of viable myocardium in infarcted and periinfarcted regions and greater number of capillaries (218 per square millimeter +/- 19 vs 119 per square millimeter +/- 17, P < .05) and arterioles (21 per square millimeter +/- 4 vs 3 per square millimeter +/- 1, P < .001). CONCLUSION: Intramyocardial transfer of VM202 improved myocardial perfusion, viability, and LV function. (c) RSNA, 2008.
PURPOSE: VM202, a newly constructed plasmid humanhepatocyte growth factor, was transferred intramyocardially after infarction for the purpose of evaluating this strategy as a therapeutic approach for protection from left ventricular (LV) remodeling. MATERIALS AND METHODS: The institutional animal care and use committee approved this study. Pigs underwent coronary artery occlusion and reperfusion and served as either control (n = 8) or VM202-treated (n = 8) animals. VM202 was transferred intramyocardially into four infarcted and four periinfarcted sites. Cardiac magnetic resonance (MR) imaging (cine, perfusion, delayed enhancement) was performed in acute (3 days) and chronic (50 days +/- 3 [standard error of the mean]) infarction. Histopathologic findings were used to characterize and quantify neovascularization. The t test was utilized to compare treated and control groups and to assess changes over time. RESULTS: In acute infarction, MR imaging estimates of function, perfusion, and viability showed no difference between the groups. In chronic infarction, however, VM202 increased maximum signal intensity and upslope at first-pass perfusion imaging and reduced infarct size at perfusion and delayed-enhancement imaging. These changes were associated with a decrease in end-diastolic (2.15 mL/kg +/- 0.12 to 1.73 mL/kg +/- 0.10, P < .01) and end-systolic (1.33 mL/kg +/- 0.07 to 0.92 mL/kg +/- 0.08, P < .001) volumes and an increase in ejection fraction (38.2% +/- 1.3 to 47.0% +/- 1.8, P < .001). In contrast, LV function deteriorated further in control animals. Compared with control animals, VM202-treated animals revealed peninsulas and/or islands of viable myocardium in infarcted and periinfarcted regions and greater number of capillaries (218 per square millimeter +/- 19 vs 119 per square millimeter +/- 17, P < .05) and arterioles (21 per square millimeter +/- 4 vs 3 per square millimeter +/- 1, P < .001). CONCLUSION: Intramyocardial transfer of VM202 improved myocardial perfusion, viability, and LV function. (c) RSNA, 2008.
Authors: Dara L Kraitchman; Mitsuaki Tatsumi; Wesley D Gilson; Takayoshi Ishimori; Dorota Kedziorek; Piotr Walczak; W Paul Segars; Hunter H Chen; Danielle Fritzges; Izlem Izbudak; Randell G Young; Michelle Marcelino; Mark F Pittenger; Meiyappan Solaiyappan; Raymond C Boston; Benjamin M W Tsui; Richard L Wahl; Jeff W M Bulte Journal: Circulation Date: 2005-08-29 Impact factor: 29.690
Authors: D D Esakof; M Maysky; D W Losordo; P R Vale; K Lathi; J O Pastore; J F Symes; J M Isner Journal: Hum Gene Ther Date: 1999-09-20 Impact factor: 5.695
Authors: Frank F Seghatol; Dipan J Shah; Silvia Diluzio; David Bello; Maryl R Johnson; William G Cotts; Jenny A O'Donohue; Robert O Bonow; Mihai Gheorghiade; Vera H Rigolin Journal: Am J Cardiol Date: 2004-04-01 Impact factor: 2.778
Authors: John A Kessler; Aziz Shaibani; Christine N Sang; Mark Christiansen; David Kudrow; Aaron Vinik; Nari Shin Journal: Clin Transl Sci Date: 2021-02-02 Impact factor: 4.689